PS21 - 103. Multipotent pancreatic progenitor cells in 3D culture of human pancreatic ductal tissue: potential relevance for beta cell therapy in Type 1 diabetes

2012 ◽  
Vol 10 (3) ◽  
pp. 172-172
Author(s):  
Nerys A. Williams ◽  
Cindy J.M. Loomans ◽  
Leon C.A. van Gurp ◽  
Femke C.A.S. Ringnalda ◽  
Toshiro Sato ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Therapy ◽  
Beta Cell ◽  
Progenitor Cells ◽  
3D Culture ◽  
Pancreatic Progenitor ◽  
Pancreatic Progenitor Cells ◽  
Ductal Tissue

294-OR: Type 1 Diabetes Patients with Residual Beta-Cell Function Display Improved Time in Euglycemia and Less Glycaemic Fluctuation after Exercise

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 294-OR
Author(s):  
GUY S. TAYLOR ◽  
KIERAN SMITH ◽  
JADINE SCRAGG ◽  
AYAT BASHIR ◽  
RICHARD A. ORAM ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Diabetes Patients

scholarly journals Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route

2020 ◽  
Vol 21 (5) ◽  
pp. 1598 ◽  
Author(s):  
Johnny Ludvigsson
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Human Subjects ◽  
Subcutaneous Administration ◽  
Acid Decarboxylase ◽  
Recent Onset ◽  
Prevention Trials

Autoantigen treatment has been tried for the prevention of type 1 diabetes (T1D) and to preserve residual beta-cell function in patients with a recent onset of the disease. In experimental animal models, efficacy was good, but was insufficient in human subjects. Besides the possible minor efficacy of peroral insulin in high-risk individuals to prevent T1D, autoantigen prevention trials have failed. Other studies on autoantigen prevention and intervention at diagnosis are ongoing. One problem is to select autoantigen/s; others are dose and route. Oral administration may be improved by using different vehicles. Proinsulin peptide therapy in patients with T1D has shown possible minor efficacy. In patients with newly diagnosed T1D, subcutaneous injection of glutamic acid decarboxylase (GAD) bound to alum hydroxide (GAD-alum) can likely preserve beta-cell function, but the therapeutic effect needs to be improved. Intra-lymphatic administration may be a better alternative than subcutaneous administration, and combination therapy might improve efficacy. This review elucidates some actual problems of autoantigen therapy in the prevention and/or early intervention of type 1 diabetes.

scholarly journals Combined Etanercept, GAD‐alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes

2021 ◽  
Author(s):  
Johnny Ludvigsson ◽  
Indusmita Routray ◽  
Tore Vigård ◽  
Ragnar Hanås ◽  
Björn Rathsman ◽  
...  
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Pilot Trial ◽  
Recent Onset ◽  
Onset Type ◽  
Open Pilot
Sign in / Sign up

Export Citation Format

Share Document